Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas حسب Malena Sibaja Leyton (18400983)

"…Moreover, annual colony losses also decreased with higher abundance of surrounding forested area. …"

ANN architecture. حسب Abdelfattah Dani (22226715)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

Illustration of BSC control using ANN for WECS. حسب Abdelfattah Dani (22226715)

Performance comparison between the OTC-FOC and ANN-BSC. حسب Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. حسب Abdelfattah Dani (22226715)

Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression. حسب Lei Li (29537)

"…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…"

Bidimensional High-Low Frequency (HF, LF) plane representation of the interaction among Phase and High-Low Clarity Groups_: In the Low Clarity (LC) group there was a larg... حسب David Vagni (8060432)

الموضوعات:

THD for the stator current i_sb (ANN-BSC). حسب Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. حسب Abdelfattah Dani (22226715)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)